Skip to main content

Table 1 Baseline characteristics of COPD patients and healthy controls*

From: IL6 and CRPhaplotypes are associated with COPD risk and systemic inflammation: a case-control study

Characteristics Controls
N = 195
COPD
N = 355
P-value
Years of age 54.3 (7.3) 64.2 (9.4) <0.001
Male, N (%) 94 (48) 219 (62) 0.002
Current smoker, N (%) 115 (59%) 90 (25%) <0.001
Tobacco consumption, pack years-smoked 29.6 (14.8) 39.9 (18.5) <0.001
FEV1, liters 3.2 (0.7) 1.1 (0.5) <0.001
FEV1,%pred 103.3 (15.1) 41.9 (16.0) <0.001
FEV1/FVC, % 78.3 (5.3) 42.0 (11.9) <0.001
FVC, liters 4.1 (0.9) 3.0 (0.9) <0.001
FVC,%pred 109.3 (16.8) 86.3 (21.1) <0.001
BMI, kg/m2 26.4 (3.7) 25.0 (5.0) <0.001
Hypertension, N (%) 33 (17%) 88 (25%) 0.01
PaO2, kPa - 9.2 (1.37)  
PaCO2, kPa - 5.5 (0.80)  
Long-term oxygen therapy, N (%) - 82 (23.43)  
6 minute walking distance, meters - 420.1 (127.9)  
Maximum workload, watts - 72.6 (33.9)  
Maximum workload,% pred - 56.6 (25.2)  
MRC dyspnea score - 3 (2–4)  
BODE index   4.3 (2.1)  
Systolic blood pressure, mm/Hg - 135.9 (23.31)  
Diastolic blood pressure, mm/Hg - 81.1 (13.09)  
Charlson co morbidity index‡ - 1 (1–8)  
CRP, mg/L 1.3 (0.2–3.19) 4.6 (1.3–11.09) <0.001
IL-6, pg/mL 0.7 (0.45–1.38) 2.1 (1.15–4.24) <0.001
Fibrinogen, g/L 3.3 (3.00–3.60) 3.6 (3.23–3.82) <0.001
Number of plasma markers
in the top quartile:
   <0.001
   0, N (%) 155 (79.4%) 159 (44.5%)  
   1, N (%) 29 (14.4%) 88 (24.2%)  
   2–3, N (%) 10 (5.2%) 118 (31.3%)  
CRP < 1 mg/L 93 (47.9%) 68 (19.2%) <0.001
CRP 1–3 mg/L 51 (26.3%) 81 (22.8%)  
CRP 3–10 mg/L 40 (20.6%) 109 (30.7%)  
CRP > 10 mg/L 10 (5.2%) 97 (27.3%)  
  1. *Data presented as mean (standard deviation), median (inter quartile range) or No (%) unless otherwise stated
  2. †Hypertension was defined as blood pressure > 140/90 mmHg or need for antihypertensive treatment.
  3. ‡ Median (range)